Boston Scientific Corp. stock: Down 35% but analysts see rebound potential

Boston Scientific shares have plunged 35% in six months amid growth concerns and legal issues, trading near 52-week lows—yet major analysts maintain buy ratings with targets well above current levels. For investors eyeing medtech recovery plays, this could signal a buying opportunity in a leader of cardiology and electrophysiology devices. ISIN: US10117L1017

Boston Scientific Corp. stock has taken a beating lately, dropping about 35% over the past six months and hovering near its 52-week low around $62 on the NYSE in USD. You might be wondering if this dip presents a rare entry point into a medtech powerhouse or if deeper troubles lurk beneath the surface. With upcoming Q1 earnings on April 22, 2026, and a portfolio dominating cardiology and electrophysiology, the company remains a key player for global investors seeking exposure to innovative medical devices.

As of: 06.04.2026

By Elena Harper, Senior Medtech Analyst: Boston Scientific leads in minimally invasive devices, powering treatments that save lives in heart rhythm management and beyond.

Why Boston Scientific Matters in Medtech

You know how heart disease remains the world's leading killer, right? Boston Scientific steps in with a broad lineup of devices that tackle everything from stents to pacemakers and advanced electrophysiology tools for treating irregular heartbeats. Their focus on minimally invasive procedures means faster recoveries and better outcomes for patients, which drives demand across hospitals in the U.S., Europe, and emerging markets.

The company's strength lies in its innovation pipeline, particularly in the electrophysiology (EP) division, where tools like ablation catheters help restore normal heart rhythms. Even amid recent volatility, Boston Scientific's revenue grew nearly 20% in recent quarters, showcasing resilience in a sector hungry for tech upgrades. For you as an investor, this positions BSX as a bet on aging populations and rising procedure volumes worldwide.

What sets them apart is their global footprint—over 50% of sales come from outside the U.S.—making it relevant whether you're trading from New York, London, or Singapore. Their acquisition strategy, including big moves like the $14.5 billion deal mentioned in reports, aims to bolster this edge, though integration risks are real.

Recent Stock Slide: What Triggered It

The big drop hit on February 4, 2026, with shares plunging 17.6% in one session after business updates and outlook fell short of sky-high expectations. Fast forward to today, and BSX trades around $62.82 on the NYSE in USD, up slightly today but still down sharply from highs near $109.50. Institutional ownership remains high at 89.07%, with funds like Rathbones Group PLC boosting stakes by 20.9% in Q4 2025, adding over 477,000 shares worth about $263 million.

This isn't just noise— a class-action lawsuit alleges executives overstated EP division growth, adding pressure as the company integrates major acquisitions. You can see why sentiment has soured, but strong Q4 2025 results—with EPS of $0.80 beating estimates and revenue up 15.9% to $5.29 billion—show the core business humming. Guidance for FY2026 EPS of 3.43-3.49 and Q1 at 0.78-0.80 keeps the bar set high.

For you, this volatility underscores medtech's sensitivity to execution risks, but also opportunities when shares overshoot to the downside. Watch volume at 13.90 million shares today—investors are paying attention.

Analyst Views: Mostly Bullish Despite Cuts

Reputable analysts largely stick with positive stances on Boston Scientific, even after recent price target trims. Evercore ISI's Vijay Kumar lowered their target from $96 to $80 while keeping an Outperform rating, citing ongoing strengths. Needham reiterated Buy at $97 on March 30, 2026, as did RBC Capital with Outperform at $115.

Raymond James shifted to Outperform from a higher target of $97 to $88 on the same date, while Goldman Sachs cut to $93 but held Buy on March 27. Piper Sandler maintained Overweight post recent device feedback, with UBS, Truist, and others echoing Buy or Outperform ratings and targets from $92 to $115. Consensus from 37 firms points to Outperform (1.7 rating), with average target $101.71—implying over 60% upside from $62.42 levels.

You'll find this mix reflects caution on near-term EP slowdowns but confidence in long-term drivers like new approvals and revenue growth. Average targets range $83 to $124, with GuruFocus GF Value at $115.81 suggesting deep undervaluation. No major sells in sight—bullish tilt for patient investors.

Business Model and Growth Drivers

At its core, Boston Scientific thrives on a franchise model built around high-margin, recurring revenue from implants and procedures. Their cardiology segment, including WATCHMAN devices for stroke prevention, leads markets with strong adoption. Electrophysiology tools for AFib treatment represent a massive addressable market as arrhythmia cases rise globally.

Revenue diversification helps: MedSurg and Rhythm & Neuro divisions complement the core, with organic growth targeted at 10.5-12% for 2026. Acquisitions expand this, but you need to track integration success. For U.S. and European investors, regulatory wins like the Asurys system could catalyze upside.

Financially solid with net margins at 14.44%, ROE 19.63%, quick ratio 1.08, and debt-to-equity 0.46, BSX supports growth without excessive leverage. PEG ratio around 0.58 screams undervalued per some metrics—key for your portfolio screening.

Risks and What to Watch Next

Legal scrutiny from the class-action suit could drag on sentiment, especially if EP growth normalizes slower than hoped. Earnings on April 22, 2026, loom large—beat on revenue and guidance, and shares could snap back; miss, and more pain follows. Competition from Medtronic and others intensifies in devices.

Macro risks like healthcare spending cuts in Europe or U.S. reimbursement changes hit hard. Beta of 0.78 offers some defense, but 52-week range $61.24-$109.50 shows swings. Watch insider sales, like CEO Mahoney's 160,901 shares at $93.49 in February—contextual, not alarming.

As a global investor, track Q1 results for EP updates, acquisition progress, and 2026 reaffirmation. New product launches could reignite momentum. If you're buying now, size positions carefully around these catalysts.

Should You Buy BSX Stock Now?

Here's the bottom line for you: Boston Scientific trades at depressed levels with strong fundamentals, high institutional interest, and analyst upside calls averaging over 60%. Undervaluation metrics like low PEG support a rebound case, especially pre-earnings where history shows pre-report gains.

But it's not risk-free—legal overhang and growth normalization demand caution. If your horizon is 12+ months and you believe in medtech tailwinds, yes, consider accumulating on weakness. Diversify, watch April 22 earnings closely, and align with your risk tolerance.

For U.S., European, or global portfolios, BSX offers growth at a value price in a vital sector. Stay informed on trial outcomes and guidance—those will dictate the next move.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.